Longboard Pharmaceuticals, Inc. Total Liabilities
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|
| Total Liabilities | $3,135.0K | $5,629.0K | $9,146.0K | $9,774.0K |
Longboard Pharmaceuticals, Inc. (LBPH) Total Liabilities comparison analysis
General
LTM Total Liabilities
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
LBPH key stats
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.0 |
% margin | 0.0 0.0% | (0.0) 0.0% | (0.0) 0.0% | (0.0) 0.0% |
| Operating Expenses | 14.4 | 27.8 | 44.8 | 56.8 |
| Research & Development Expenses (R&D) | 4.6 | 19.8 | 34.6 | 43.8 |
| Selling, General & Administrative Expenses (SG&A) | 9.8 | 8.1 | 10.2 | 13.0 |
% margin | (14.4) 0.0% | (27.8) 0.0% | (44.8) 0.0% | (56.8) 0.0% |
| Interest Income | 0.0 | 0.1 | 0.8 | 2.4 |
| Interest Expense | 0.0 | 0.0 | 0.8 | 0.0 |
| Pre-tax Income | (14.4) | (27.8) | (43.9) | (54.4) |
% effective tax rate | (0.0) 0.1% | (0.1) 0.2% | (0.9) 1.9% | 0.0 0.0% |
% margin | (14.4) 0.0% | (27.7) 0.0% | (43.1) 0.0% | (54.4) 0.0% |
| EPS | (0.82) | (1.62) | (2.51) | (2.39) |
| Diluted EPS | (0.82) | (1.62) | (2.51) | (2.39) |
% margin | (14.4) 0.0% | (27.8) 0.0% | (44.8) 0.0% | (56.8) 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Longboard Pharmaceuticals, Inc.'s Total Liabilities?
As of today, Longboard Pharmaceuticals, Inc.'s last 12-month Total Liabilities is $21.8M, based on the financial report for Sep 30, 2024 (Q3’2024).
2) What is Longboard Pharmaceuticals, Inc.'s Total Liabilities growth rate?
Over the last year, Longboard Pharmaceuticals, Inc.'s Total Liabilities growth was 219.9%. The average annual Total Liabilities growth rates for Longboard Pharmaceuticals, Inc. have been 75.4% over the past three years, N/A over the past five years.
3) Is Longboard Pharmaceuticals, Inc.'s Total Liabilities growth rate Good?
Over the last year, Longboard Pharmaceuticals, Inc.'s Total Liabilities growth was 219.9%, which is higher than industry growth of 0.1%. It indicates that Longboard Pharmaceuticals, Inc.'s Total Liabilities growth is Good.